Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 368

1.

Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients.

Gresham G, Hendifar AE, Spiegel B, Neeman E, Tuli R, Rimel BJ, Figlin RA, Meinert CL, Piantadosi S, Shinde AM.

NPJ Digit Med. 2018 Jul 5;1:27. doi: 10.1038/s41746-018-0032-6. eCollection 2018.

2.

Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous.

Reed JP, Posadas EM, Figlin RA.

J Clin Oncol. 2019 Aug 10;37(23):1987-1989. doi: 10.1200/JCO.19.00639. Epub 2019 Jun 20. No abstract available.

PMID:
31232668
3.

Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer.

Neeman E, Gresham G, Ovasapians N, Hendifar A, Tuli R, Figlin R, Shinde A.

Oncologist. 2019 Jun 21. pii: theoncologist.2018-0882. doi: 10.1634/theoncologist.2018-0882. [Epub ahead of print]

PMID:
31227648
4.

Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma.

Uche A, Sila C, Tanoura T, Yeh J, Bhowmick N, Posadas E, Figlin R, Gong J.

Case Rep Urol. 2019 Feb 13;2019:6769017. doi: 10.1155/2019/6769017. eCollection 2019.

5.

Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma.

Adashek JJ, Salgia MM, Posadas EM, Figlin RA, Gong J.

Clin Genitourin Cancer. 2019 Jun;17(3):e454-e460. doi: 10.1016/j.clgc.2019.01.004. Epub 2019 Jan 15. Review.

PMID:
30733185
6.

Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma.

Reed JP, Posadas EM, Figlin RA.

Expert Rev Anticancer Ther. 2019 Mar;19(3):259-271. doi: 10.1080/14737140.2019.1573678. Epub 2019 Feb 4.

PMID:
30669895
7.

Highlights in kidney cancer from the American Society of Clinical Oncology Genitourinary Cancers Symposium.

Figlin RA.

Clin Adv Hematol Oncol. 2018 Jun;16(6):423-425. No abstract available.

PMID:
30067613
8.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ.

Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4.

9.

Highlights in renal cell carcinoma from the Sixteenth International Kidney Cancer Symposium: commentary.

Figlin RA.

Clin Adv Hematol Oncol. 2018 Jan;16 Suppl 1(1):21-23. No abstract available.

PMID:
29742094
10.

Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance.

Lee MY, Yeon A, Shahid M, Cho E, Sairam V, Figlin R, Kim KH, Kim J.

Oncotarget. 2018 Jan 13;9(17):13231-13243. doi: 10.18632/oncotarget.24229. eCollection 2018 Mar 2.

11.

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK.

J Clin Oncol. 2018 Mar 20;36(9):867-874. doi: 10.1200/JCO.2017.74.2627. Epub 2017 Dec 19.

12.

Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?

Figlin RA, Leibovich BC, Stewart GD, Negrier S.

Ann Oncol. 2018 Feb 1;29(2):324-331. doi: 10.1093/annonc/mdx743. Review.

PMID:
29186296
13.

Wearable activity monitors in oncology trials: Current use of an emerging technology.

Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R, Meinert CL, Piantadosi S.

Contemp Clin Trials. 2018 Jan;64:13-21. doi: 10.1016/j.cct.2017.11.002. Epub 2017 Nov 9. Review.

14.

Adjuvant Pazopanib Does Not PROTECT Against Recurrence of High-Risk, Initially Localized Renal Cell Cancer but Does Provide Novel Insights.

Stewart GD, Leibovich BC, Negrier S, Figlin RA.

J Clin Oncol. 2017 Dec 10;35(35):3895-3897. doi: 10.1200/JCO.2017.75.4242. Epub 2017 Oct 25. No abstract available.

PMID:
29068785
15.

A novel machine learning approach reveals latent vascular phenotypes predictive of renal cancer outcome.

Ing N, Huang F, Conley A, You S, Ma Z, Klimov S, Ohe C, Yuan X, Amin MB, Figlin R, Gertych A, Knudsen BS.

Sci Rep. 2017 Oct 16;7(1):13190. doi: 10.1038/s41598-017-13196-4.

16.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.

PMID:
28950297
17.

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.

Lakdawalla DN, Shafrin J, Hou N, Peneva D, Vine S, Park J, Zhang J, Brookmeyer R, Figlin RA.

Value Health. 2017 Jul - Aug;20(7):866-875. doi: 10.1016/j.jval.2017.04.003. Epub 2017 May 16.

18.

Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials.

Tannir NM, Figlin RA, Gore ME, Michaelson MD, Motzer RJ, Porta C, Rini BI, Hoang C, Lin X, Escudier B.

Clin Genitourin Cancer. 2017 Jun 20. pii: S1558-7673(17)30171-4. doi: 10.1016/j.clgc.2017.06.005. [Epub ahead of print]

19.

Targeted therapies for renal cell carcinoma.

Posadas EM, Limvorasak S, Figlin RA.

Nat Rev Nephrol. 2017 Aug;13(8):496-511. doi: 10.1038/nrneph.2017.82. Epub 2017 Jul 10. Review.

PMID:
28691713
20.

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

Zurita AJ, Gagnon RC, Liu Y, Tran HT, Figlin RA, Hutson TE, D'Amelio AM Jr, Sternberg CN, Pandite LN, Heymach JV.

Br J Cancer. 2017 Aug 8;117(4):478-484. doi: 10.1038/bjc.2017.206. Epub 2017 Jul 6.

21.

Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.

Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, Williams JA, Hutson TE.

Clin Genitourin Cancer. 2017 Oct;15(5):526-533. doi: 10.1016/j.clgc.2017.02.006. Epub 2017 Feb 27.

PMID:
28330808
22.

Circulating tumor cells in prostate cancer: beyond enumeration.

Chen JF, Lu YT, Cheng S, Tseng HR, Figlin RA, Posadas EM.

Clin Adv Hematol Oncol. 2017 Jan;15(1):63-73.

PMID:
28212371
23.

Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.

Kumbla RA, Figlin RA, Posadas EM.

Drugs. 2017 Jan;77(1):17-28. doi: 10.1007/s40265-016-0665-1. Review.

PMID:
27995579
24.

Adjuvant treatment for renal cell carcinoma: do we finally have a major breakthrough?

Patel DN, Figlin RA, Kim HL.

Clin Adv Hematol Oncol. 2016 Nov;14(11):907-914. Review.

PMID:
27930642
25.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.

26.

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

Motzer RJ, Escudier B, Gannon A, Figlin RA.

Oncologist. 2017 Jan;22(1):41-52. doi: 10.1634/theoncologist.2016-0197. Epub 2016 Nov 2.

27.

Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.

Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin RA.

Clin Genitourin Cancer. 2017 Apr;15(2):291-299.e1. doi: 10.1016/j.clgc.2016.08.013. Epub 2016 Aug 18.

PMID:
27638198
28.

Third-Line Treatment Options for Kidney Cancer.

Posadas EM, Limvorasak S, Figlin RA.

Oncology (Williston Park). 2016 Sep 15;30(9):813-5. No abstract available.

29.

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.

Bono P, Oudard S, Bodrogi I, Hutson TE, Escudier B, Machiels JP, Thompson JA, Figlin RA, Ravaud A, Basaran M, Porta C, Bracarda S, Brechenmacher T, Lin C, Voi M, Grunwald V, Motzer RJ.

Clin Genitourin Cancer. 2016 Oct;14(5):406-414. doi: 10.1016/j.clgc.2016.04.011. Epub 2016 Apr 27.

30.

The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Hutson TE, Thoreson GR, Figlin RA, Rini BI.

Am Soc Clin Oncol Educ Book. 2016;35:113-7. doi: 10.14694/EDBK_158892. Review.

31.

Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy.

Posadas EM, Figlin RA.

J Oncol Pract. 2016 May;12(5):424-5. doi: 10.1200/JOP.2016.012393. No abstract available.

PMID:
27170689
32.

A Rare Finding of a BRAF Mutation in Renal Cell Carcinoma with Response to BRAF-Directed Targeted Therapy.

Banerjee N, Sachdev E, Figlin RA.

Cureus. 2016 Jan 6;8(1):e449. doi: 10.7759/cureus.449.

33.

The value of surrogate endpoints for predicting real-world survival across five cancer types.

Shafrin J, Brookmeyer R, Peneva D, Park J, Zhang J, Figlin RA, Lakdawalla DN.

Curr Med Res Opin. 2016;32(4):731-9. doi: 10.1185/03007995.2016.1140027. Epub 2016 Jan 25.

PMID:
26743800
34.

Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?

Goldstein D, Rosenberg JE, Figlin RA, Townsend RR, McCann L, Carpenter C, Pandite L.

Eur J Cancer. 2016 Jan;53:96-104. doi: 10.1016/j.ejca.2015.10.006. Epub 2015 Dec 15.

PMID:
26702763
35.

Literature Review and Profile of Cancer Diseases Among Afghan Refugees in Iran: Referrals in Six Years of Displacement.

Otoukesh S, Mojtahedzadeh M, Figlin RA, Rosenfelt FP, Behazin A, Sherzai D, Cooper CJ, Nahleh ZA.

Med Sci Monit. 2015 Nov 23;21:3622-8. Review.

36.

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer.

Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO.

Mol Cancer Ther. 2015 Dec;14(12):2896-900. doi: 10.1158/1535-7163.MCT-15-0367. Epub 2015 Oct 8.

37.

Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.

Figlin RA.

Expert Opin Biol Ther. 2015;15(8):1241-8. doi: 10.1517/14712598.2015.1063610. Epub 2015 Jun 30. Review.

PMID:
26125651
38.

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.

Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM.

Cancer. 2015 Sep 15;121(18):3298-306. doi: 10.1002/cncr.29480. Epub 2015 May 29.

39.

Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.

Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, Master VA, Pal SK, Miller WH Jr, Karsh LI, Tcherepanova IY, DeBenedette MA, Williams WL, Plessinger DC, Nicolette CA, Figlin RA.

J Immunother Cancer. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.

40.

Renal cell carcinoma: An update for the practicing urologist.

Pal SK, Bergerot P, Figlin RA.

Asian J Urol. 2015 Jan;2(1):19-25. doi: 10.1016/j.ajur.2015.04.012. Epub 2015 Apr 16. Review.

41.

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB.

Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.

42.

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA.

Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50. doi: 10.1007/s00280-014-2539-0. Epub 2014 Aug 7.

43.

Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.

Pal SK, Hu A, Chang M, Figlin RA.

Clin Adv Hematol Oncol. 2014 Feb;12(2):90-9. Review.

PMID:
24892254
44.

Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.

Négrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ.

Eur J Cancer. 2014 Jul;50(10):1766-1771. doi: 10.1016/j.ejca.2014.03.012. Epub 2014 Apr 23.

45.

Kidney cancer: progress and controversies in neoadjuvant therapy.

Posadas EM, Figlin RA.

Nat Rev Urol. 2014 May;11(5):254-5. doi: 10.1038/nrurol.2014.89. Epub 2014 Apr 22.

PMID:
24752207
46.

Targeted therapy for sarcomas.

Forscher C, Mita M, Figlin R.

Biologics. 2014 Mar 17;8:91-105. doi: 10.2147/BTT.S26555. eCollection 2014. Review.

47.

Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.

Cella D, Davis MP, Négrier S, Figlin RA, Michaelson MD, Bushmakin AG, Cappelleri JC, Sandin R, Korytowsky B, Charbonneau C, Matczak E, Motzer RJ.

Cancer. 2014 Jun 15;120(12):1871-80. doi: 10.1002/cncr.28660. Epub 2014 Mar 13.

48.

Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

Pal SK, Figlin RA.

Cancer. 2014 Jun 1;120(11):1604-7. doi: 10.1002/cncr.28636. Epub 2014 Feb 27. No abstract available.

49.

Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition.

Wang Y, Sparwasser T, Figlin R, Kim HL.

Cancer Res. 2014 Apr 15;74(8):2217-28. doi: 10.1158/0008-5472.CAN-13-2928. Epub 2014 Feb 26.

50.

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, Martell B, Matczak E, Motzer RJ.

Br J Cancer. 2014 Mar 4;110(5):1125-32. doi: 10.1038/bjc.2013.832. Epub 2014 Jan 16.

Supplemental Content

Loading ...
Support Center